Key Drivers
- High gross margins
- Strong liquidity
- Thin net profitability
AIAI Summary
Pacira is no longer a binary pipeline bet but a cash‑generating, high‑gross‑margin commercial franchise whose valuation now hinges on management converting consistent Exparel volume growth into durable revenue and margin expansion via ASP recovery and GPO renegotiations—monitor sequential EPS/ASP improvement, IP litigation timelines, and GPO anniversaries as the make‑or‑break catalysts.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •High gross margins
- •Strong liquidity
- •Thin net profitability
Pacira shows strong cash generation, very high gross margins and liquidity but is constrained by thin net profits, heavy operating/R&D spend and significant long-term debt.
Price Behavior
Key Price Behavior Insights:
- •Short-term pullback
- •Neutral momentum
- •Repeated tests
PCRX is pulling back below its last month SMA (~$22.59) with neutral momentum (RSI ~56), support near $21.28 and resistance near $23.50 — reclaiming the SMA would resume upside while a failed retest risks further weakness.
Mid‑March pullback below last month
Sentiment & News
Key News Insights:
- •Record Exparel
- •Q4 earnings miss
- •Activist nomination
Pacira reported record Exparel volume but missed Q4 revenue/EPS, triggering a stock sell-off and activist nominations pushing for board change.
Expect heightened stock volatility and increased likelihood of governance-driven strategic actions (board changes or sale process)
Similar Companies in Healthcare
Other companies in the same sector with AI ratings